产品
编 号：F742523
产品类型
规格
价格
是否有货
1mg
询价
询价
5mg
询价
询价
结构图
CAS No: 1105038-73-0
产品详情
生物活性：
Abituzumab (DI17E6) is a humanised anti-integrin αV monoclonal antibody (IgG2 type). Abituzumab effectively reduces the phosphorylation of FAK, Akt and ERK. Abituzumab can be used in cancer research, particularly in prostate cancer.
体外研究：
Abituzumab (DI17E6) (0.01, 0.1, 1, 10, 30,100 μg/mL; 24 h) inhibits adhesion of PCa cells to multiple extracellular matrix proteins but not collagen IAbituzumab (100 μg/mL; 12, 18 h) inhibits inhibits motility and invasion of PCa cells.Abituzumab (0.01, 0.1, 1, 10, 30,100 μg/mL; 24 h) inhibits the ability of PCa cells to adhere to osteoblast and bone stromal cell lines.Abituzumab (100 μg/mL; 24 h) blocks integrin-mediated cell signaling in PCa cancer cell lines.
Abituzumab (DI17E6) is a humanised anti-integrin αV monoclonal antibody (IgG2 type). Abituzumab effectively reduces the phosphorylation of FAK, Akt and ERK. Abituzumab can be used in cancer research, particularly in prostate cancer.
体外研究：
Abituzumab (DI17E6) (0.01, 0.1, 1, 10, 30,100 μg/mL; 24 h) inhibits adhesion of PCa cells to multiple extracellular matrix proteins but not collagen IAbituzumab (100 μg/mL; 12, 18 h) inhibits inhibits motility and invasion of PCa cells.Abituzumab (0.01, 0.1, 1, 10, 30,100 μg/mL; 24 h) inhibits the ability of PCa cells to adhere to osteoblast and bone stromal cell lines.Abituzumab (100 μg/mL; 24 h) blocks integrin-mediated cell signaling in PCa cancer cell lines.
产品资料
Copyright©2015-2024 沪ICP备2022026524号-1
沪公网安备